{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:55:02Z","timestamp":1790762102641,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0218905","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T13:35:49Z","timestamp":1579008949000},"page":"e0218905","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["HIV infection does not alter interferon \u03b1\/\u03b2 receptor 2 expression on mucosal immune cells"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-8505","authenticated-orcid":true,"given":"Julia","family":"Ickler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Widera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario L.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"pone.0218905.ref001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mi.2007.1","article-title":"HIV infection and the gastrointestinal immune system","volume":"1","author":"JM Brenchley","year":"2008","journal-title":"Mucosal Immunol"},{"key":"pone.0218905.ref002","article-title":"Microbial Translocation in the Pathogenesis of HIV Infection and AIDS","volume":"23","author":"G Marchetti","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"pone.0218905.ref003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COH.0000000000000234","article-title":"Microbial translocation and microbiome dysbiosis in HIV-associated immune activation","volume":"11","author":"AS Zevin","year":"2016","journal-title":"Curr Opin HIV AIDS. NIH Public Access"},{"key":"pone.0218905.ref004","first-page":"572.1","article-title":"CD4 + T Cell Depletion During All Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract","volume":"116","author":"JM Brenchley","year":"2017","journal-title":"Pediatrics"},{"key":"pone.0218905.ref005","article-title":"Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood","author":"T Schneider","year":"1995","journal-title":"Gut"},{"key":"pone.0218905.ref006","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.it.2008.07.010","article-title":"Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine","volume":"29","author":"IM Belyakov","year":"2008","journal-title":"Trends Immunol. Elsevier Current Trends"},{"key":"pone.0218905.ref007","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.1128\/JVI.77.21.11708-11717.2003","article-title":"Severe CD4 T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy","volume":"77","author":"M Guadalupe","year":"2003","journal-title":"J Virol"},{"key":"pone.0218905.ref008","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1202::AID-IMMU1202>3.0.CO;2-O","article-title":"Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection","volume":"29","author":"C Lapenta","year":"1999","journal-title":"Eur J Immunol"},{"key":"pone.0218905.ref009","doi-asserted-by":"crossref","first-page":"e1005254","DOI":"10.1371\/journal.ppat.1005254","article-title":"Interferon-\u03b1 Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms","volume":"11","author":"MS Harper","year":"2015","journal-title":"PLOS Pathog"},{"key":"pone.0218905.ref010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0079-6603(08)60026-4","article-title":"The interferon genes","volume":"33","author":"C Weissmann","year":"1986","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"pone.0218905.ref011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygeno.2004.03.003","article-title":"Characterization of the type I interferon locus and identification of novel genes","volume":"84","author":"MP Hardy","year":"2004","journal-title":"Genomics"},{"key":"pone.0218905.ref012","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors-distribution and regulation","volume":"90","author":"NA De Weerd","year":"2012","journal-title":"Immunol Cell Biol. Nature Publishing Group"},{"key":"pone.0218905.ref013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2018.02.002","article-title":"Interferon \u03b1 subtypes in HIV infection","volume":"40","author":"K Sutter","year":"2018","journal-title":"Cytokine Growth Factor Rev. Elsevier"},{"key":"pone.0218905.ref014","first-page":"129","article-title":"The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFN\u03b1 on pleomorphic sarcoma cells","volume":"26","author":"C Gazziola","year":"2005","journal-title":"Int J Oncol. Spandidos Publications"},{"key":"pone.0218905.ref015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V97.2.473","article-title":"The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties","volume":"97","author":"MP Hardy","year":"2001","journal-title":"Blood"},{"key":"pone.0218905.ref016","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/archneur.63.11.1579","article-title":"Interferon Inhibitory Activity in Patients With Multiple Sclerosis","volume":"63","author":"K Chadha","year":"2006","journal-title":"Arch Neurol"},{"key":"pone.0218905.ref017","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/cncr.11843","article-title":"Free interferon-?\/? receptors in the circulation of patients with adenocarcinoma","volume":"98","author":"JLS Ambrus","year":"2003","journal-title":"Cancer"},{"key":"pone.0218905.ref018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000331230","article-title":"Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer","volume":"79","author":"S Tanaka","year":"2012","journal-title":"Pathobiology"},{"key":"pone.0218905.ref019","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/hep.510300516","article-title":"Serum Levels of Soluble Interferon Alfa \/ Beta Receptor as an Inhibitory Factor of Interferon in the Patients With Chronic Hepatitis C","volume":"30","author":"E Mizukoshi","year":"1999","journal-title":"Hepatology"},{"key":"pone.0218905.ref020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jir.2017.0076","article-title":"Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection","volume":"37","author":"Y Li","year":"2017","journal-title":"J Interf Cytokine Res"},{"key":"pone.0218905.ref021","first-page":"3719","article-title":"Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections","volume":"83","author":"AR Stacey","year":"2009","journal-title":"J Virol. American Society for Microbiology (ASM)"},{"key":"pone.0218905.ref022","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/aid.1991.7.375","article-title":"Interferon-Alpha and Tumor Necrosis Factor-Alpha in Serum of Patients in Various Stages of HIV-1 Infection","volume":"7","author":"M von SYDOW","year":"1991","journal-title":"AIDS Res Hum Retroviruses"},{"key":"pone.0218905.ref023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94366","article-title":"Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection","volume":"2","author":"L Cheng","year":"2017","journal-title":"JCI Insight"},{"key":"pone.0218905.ref024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.20411\/pai.v1i1.125","article-title":"Interferons and HIV Infection: The Good, the Bad, and the Ugly","volume":"1","author":"NS Utay","year":"2016","journal-title":"Pathog Immun"},{"key":"pone.0218905.ref025","article-title":"Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells","author":"AKR Kwaa","year":"2019"},{"key":"pone.0218905.ref026","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1172\/JCI90745","article-title":"Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs","volume":"127","author":"L Cheng","year":"2017","journal-title":"J Clin Invest"},{"key":"pone.0218905.ref027","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00042560-199912010-00005","article-title":"A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells\/mm(3). Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group","volume":"22","author":"B Alston","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0218905.ref028","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11904-014-0244-6","article-title":"Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy","volume":"12","author":"SE Bosinger","year":"2015","journal-title":"Curr HIV\/AIDS Rep. Springer US"},{"key":"pone.0218905.ref029","unstructured":"Katabira ET, Sewankambo NK, Mugerwa RD, Belsey EM, Mubiru FX, Othieno C, et al. Lack of eYcacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial [Internet]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1758122\/pdf\/v074p00265.pdf"},{"key":"pone.0218905.ref030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrmicro3449","article-title":"HIV-1 and interferons: Who\u2019s interfering with whom?","volume":"13","author":"T Doyle","year":"2015","journal-title":"Nat Rev Microbiol. Nature Publishing Group"},{"key":"pone.0218905.ref031","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1128\/JVI.00451-16","article-title":"Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo","volume":"90","author":"KJ Lavender","year":"2016","journal-title":"J Virol"},{"key":"pone.0218905.ref032","first-page":"78412","article-title":"Gene therapy with plasmids encoding IFN-\u03b2 or IFN-\u03b114 confers long-term resistance to HIV-1 in humanized mice","volume":"7","author":"S Abraham","year":"2016","journal-title":"Oncotarget. Impact Journals, LLC"},{"key":"pone.0218905.ref033","article-title":"Concurrent administration of IFN\u03b114 and cART in TKO-BLT mice enhances suppression of HIV-1 viremia but does not eliminate the latent reservoir","volume":"9","author":"K Sutter","year":"2019","journal-title":"Sci Rep. Nature Research"},{"key":"pone.0218905.ref034","doi-asserted-by":"crossref","first-page":"e1006226","DOI":"10.1371\/journal.ppat.1006226","article-title":"The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria","volume":"13","author":"AC Yoder","year":"2017","journal-title":"PLOS Pathog. Public Library of Science"},{"key":"pone.0218905.ref035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000001280","article-title":"Increased expression of the Type i interferon receptor on CD4 + T lymphocytes in HIV-1-infected individuals","volume":"74","author":"MS Killian","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0218905.ref036","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clim.2008.12.003","article-title":"Evidence for Dendritic Cell-Dependent CD4+ T Helper-1 Type Responses to Commensal Bacteria in Normal Human Intestinal Lamina Propria","volume":"131","author":"R Howe","year":"2010","journal-title":"Clini Immunol"},{"key":"pone.0218905.ref037","doi-asserted-by":"crossref","first-page":"13852","DOI":"10.1128\/JVI.00904-07","article-title":"Nef-Mediated Enhancement of Virion Infectivity and Stimulation of Viral Replication Are Fundamental Properties of Primate Lentiviruses","volume":"81","author":"J M\u00fcnch","year":"2007","journal-title":"J Virol"},{"key":"pone.0218905.ref038","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1128\/JVI.76.16.8455-8459.2002","article-title":"NOTES Nef Enhances Human Immunodeficiency Virus Type 1 Infectivity and Replication Independently of Viral Coreceptor Tropism","volume":"76","author":"A Papkalla","year":"2002","journal-title":"J Virol"},{"key":"pone.0218905.ref039","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1515\/labmed-2015-0020","article-title":"Expression of interferon type-I receptor isoforms, clinical response and development of neutralizing antibodies in multiple sclerosis patients\u2013results of a prospective study","volume":"40","author":"A Bauer","year":"2016","journal-title":"LaboratoriumsMedizin. De Gruyter"},{"key":"pone.0218905.ref040","doi-asserted-by":"crossref","first-page":"e58813","DOI":"10.1371\/journal.pone.0058813","article-title":"Activation of the Type I Interferon Pathway Is Enhanced in Response to Human Neuronal Differentiation","volume":"8","author":"JR Farmer","year":"2013","journal-title":"PLoS One. Public Library of Science"},{"key":"pone.0218905.ref041","first-page":"141","article-title":"Comparable potency of IFNalpha2 and IFNbeta on immediate JAK\/STAT activation but differential down-regulation of IFNAR2","volume":"407","author":"Z Marijanovic","year":"2007","journal-title":"Biochem J. Portland Press Ltd"},{"key":"pone.0218905.ref042","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000001280","article-title":"Increased expression of the Type i interferon receptor on CD4+T lymphocytes in HIV-1-infected individuals","volume":"74","author":"MS Killian","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0218905.ref043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2004.02.003","article-title":"A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets","volume":"50","author":"S Tochizawa","year":"2004","journal-title":"J Pharmacol Toxicol Methods. Elsevier"},{"key":"pone.0218905.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00526","article-title":"Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types","volume":"5","author":"E Tomasello","year":"2014","journal-title":"Front Immunol"},{"key":"pone.0218905.ref045","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/JVI.02749-15","article-title":"Hemagglutinin of Influenza A Virus Antagonizes Type I Interferon (IFN) Responses by Inducing Degradation of Type I IFN Receptor 1","volume":"90","author":"C Xia","year":"2016","journal-title":"J Virol"},{"key":"pone.0218905.ref046","article-title":"Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling","volume":"5","author":"D Jia","year":"2010","journal-title":"PLoS One"},{"key":"pone.0218905.ref047","unstructured":"Samarajiwa SA, Mangan NE, Hardy MP, Najdovska M, Dubach D, Braniff S-J, et al. TLR4-Mediated Septic Shock Type I IFN Signaling and Exacerbates Soluble IFN Receptor Potentiates In Vivo. 2014;."},{"key":"pone.0218905.ref048","unstructured":"Fatakdawala T, Skawinski M, Ferriera J, Stauffer T, Lavoie T. Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases\u2014ACR Meeting Abstracts [Internet]. 2013 [cited 2 Jun 2019]. Available: https:\/\/acrabstracts.org\/abstract\/soluble-type-i-interferon-receptor-2-is-elevated-by-interferon-treatment-and-in-certain-autoimmune-diseases\/"},{"key":"pone.0218905.ref049","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/1352458516667564","article-title":"Decreased soluble IFN-\u03b2 receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker","volume":"23","author":"T \u00d3rpez-Zafra","year":"2017","journal-title":"Mult Scler J. SAGE PublicationsSage UK: London, England"},{"key":"pone.0218905.ref050","doi-asserted-by":"crossref","unstructured":"Abudulai L, CHa L, Fernandez S, French M. INCREASED INTERFERON-ALPHA ACTIVITY MAY CONTRIBUTE TO DEFECTS OF B CELLS AND ANTIBODY PRODUCTION CAUSED BY HIV-1 INFECTION. In: Jornal of Virus Eradication, Abstratcs of the IAS 2016 Towards and HIV Cure Symposium [Internet]. 2016 [cited 2 Jun 2019]. http:\/\/viruseradication.com\/abstract-details.php?abstract_id=1002","DOI":"10.1016\/S2055-6640(20)30947-X"},{"key":"pone.0218905.ref051","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/jir.2012.0117","article-title":"Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy","volume":"33","author":"SY Fuchs","year":"2013","journal-title":"J Interf Cytokine Res. Mary Ann Liebert, Inc."},{"key":"pone.0218905.ref052","first-page":"282","article-title":"Binding and activity of all human alpha interferon subtypes","volume":"56","author":"TB Lavoie","year":"2011","journal-title":"Cytokine. Elsevier Ltd"},{"key":"pone.0218905.ref053","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","article-title":"Differential Receptor Subunit Affinities of Type I Interferons Govern Differential Signal Activation","volume":"366","author":"E Jaks","year":"2007","journal-title":"J Mol Biol"},{"key":"pone.0218905.ref054","article-title":"Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment","author":"K V. Katlinski","year":"2017","journal-title":"Cancer Cell"},{"key":"pone.0218905.ref055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/emboj\/cdg038","article-title":"The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression","volume":"22","author":"J Ragimbeau","year":"2003","journal-title":"EMBO J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0218905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T23:18:53Z","timestamp":1695597533000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0218905"}},"subtitle":[],"editor":[{"given":"Yolande","family":"Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0218905","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/688440","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,14]]}}}